LI-RADS ancillary features favoring benignity: is there a role in LR-5 observations?
Cirrhosis
Gadoxetate disodium
Hepatocellular carcinoma
Liver
Magnetic resonance imaging
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
received:
25
05
2021
accepted:
11
08
2021
revised:
29
07
2021
pubmed:
22
9
2021
medline:
15
2
2022
entrez:
21
9
2021
Statut:
ppublish
Résumé
The Liver Imaging Reporting and Data System algorithm allows category downgrade in the presence of ancillary features (AFs) favoring benignity, even in observations categorized as LR-5. This study aims to assess the role of AFs favoring benignity in LR-5 observations and their impact on category downgrade. This study included high-risk patients with at least one LR-5 observation imaged with gadoxetate disodium MRI. Three readers with different experience levels independently evaluated the presence of AFs favoring malignancy (not hepatocellular carcinoma (HCC) in particular and HCC in particular) and AFs favoring benignity. Category downgrade was considered possible in the presence of ≥ 1 AF favoring benignity and no AF favoring malignancy. Correlation between observations size and number of AFs was assessed using Spearman's rank correlation coefficient. Cohen's kappa (k) test was used to assess inter-reader agreement. The final study cohort included 162 LR-5 (mean size: 23 ± 16 mm) in 119 patients. AFs favoring benignity were reported in 9 (5.6%), 20 (12.3%), and 10 (6.2%) LR-5 observations by reader 1, reader 2, and reader 3, respectively. Hepatobiliary phase isointensity was observed in 6 (3.7%), 2 (1.2%), and 7 (4.3%) observations, respectively. Category downgrade was considered possible in only one (0.6%) observation by reader 1 and reader 3. There was a significant correlation between observation size and number of AFs favoring malignancy (p < 0.001), not HCC in particular (p ≤ 0.010), and favoring HCC in particular (p < 0.001). Inter-reader agreement of AFs favoring benignity was poor to moderate (k range: - 0.01, 0.43). AFs favoring benignity are not uncommon in LR-5 observations, but category downgrade is exceptional. • Ancillary features favoring benignity are encountered in 5.6-12.3% of observations categorized as LR-5. • Category downgrade of LR-5 observations is very rare (0.6% of observations) in the presence of AFs favoring benignity due to the high prevalence (98-99%) of ancillary features favoring malignancy in LR-5 observations. • The inter-reader agreement of ancillary features favoring benignity is poor to moderate (k range: - 0.01, 0.43) in readers with different levels of experience.
Identifiants
pubmed: 34545444
doi: 10.1007/s00330-021-08267-0
pii: 10.1007/s00330-021-08267-0
doi:
Substances chimiques
Contrast Media
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1804-1812Informations de copyright
© 2021. European Society of Radiology.
Références
American College of Radiology. CT/MRI Liver imaging reporting and data system v2018 core. https://www.acr.org/Clinical-Resources/Reporting-and-Data-Systems/LI-RADS/CT-MRI-LI-RADS-v2018 . Accessed May 2021
Marrero JA, Kulik LM, Sirlin CB et al (2018) Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 68:723–750
pubmed: 29624699
doi: 10.1002/hep.29913
European Association for the Study of the Liver (2018) EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 69:182–236
doi: 10.1016/j.jhep.2018.03.019
Korean Liver Cancer Association; National Cancer Center (2019) 2018 Korean Liver Cancer Association-National Cancer Center Korea practice guidelines for the management of hepatocellular carcinoma. Gut Liver 13:227–299
doi: 10.5009/gnl19024
Omata M, Cheng AL, Kokudo N et al (2017) Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 11:317–370
pubmed: 28620797
doi: 10.1007/s12072-017-9799-9
Kudo M, Matsui O, Izumi N et al (2014) JSH consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3:458–468
pubmed: 26280007
pmcid: 4531423
doi: 10.1159/000343875
Chernyak V, Tang A, Flusberg M et al (2018) LI-RADS® ancillary features on CT and MRI. Abdom Radiol (NY) 43:82–100
doi: 10.1007/s00261-017-1220-6
Cerny M, Chernyak V, Olivié D et al (2018) LI-RADS Version 2018 ancillary features at MRI. Radiographics 38:1973–2001
pubmed: 30289735
doi: 10.1148/rg.2018180052
Choi SH, Byun JH, Kim SY et al (2016) Liver Imaging Reporting and Data System v2014 with gadoxetate disodium-enhanced magnetic resonance imaging: validation of LI-RADS category 4 and 5 criteria. Invest Radiol 51:483–490
pubmed: 26885632
doi: 10.1097/RLI.0000000000000258
Joo I, Lee JM, Lee DH, Ahn SJ, Lee ES, Han JK (2017) Liver imaging reporting and data system v2014 categorization of hepatocellular carcinoma on gadoxetic acid-enhanced MRI: comparison with multiphasic multidetector computed tomography. J Magn Reson Imaging 45:731–740
pubmed: 27474328
doi: 10.1002/jmri.25406
Boatright C, Peterson J, Williams VL, Best S, Ash R (2020) LI-RADS v2018: utilizing ancillary features on gadoxetate-enhanced MRI to modify final LI-RADS category. Abdom Radiol (NY) 45:3136–3143
doi: 10.1007/s00261-020-02479-6
Cerny M, Bergeron C, Billiard JS et al (2018) LI-RADS for MR imaging diagnosis of hepatocellular carcinoma: performance of major and ancillary features. Radiology 288:118–128
pubmed: 29634435
doi: 10.1148/radiol.2018171678
Min JH, Kim JM, Kim YK et al (2018) Prospective intraindividual comparison of magnetic resonance imaging with gadoxetic acid and extracellular contrast for diagnosis of hepatocellular carcinomas using the Liver Imaging Reporting and Data System. Hepatology 68:2254–2266
pubmed: 30070365
doi: 10.1002/hep.30122
Paisant A, Vilgrain V, Riou J et al (2020) Comparison of extracellular and hepatobiliary MR contrast agents for the diagnosis of small HCCs. J Hepatol 72:937–945
pubmed: 31870951
doi: 10.1016/j.jhep.2019.12.011
Khouri Chalouhi C, Vernuccio F, Rini F et al (2019) Hepatobiliary phase in cirrhotic patients with different model for end-stage liver disease score: comparison of the performance of gadoxetic acid to gadobenate dimeglumine. Eur Radiol 29:3090–3099
pubmed: 30547205
doi: 10.1007/s00330-018-5884-2
Zech CJ, Ba-Ssalamah A, Berg T et al (2020) Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging. Eur Radiol 30:370–382
pubmed: 31385048
doi: 10.1007/s00330-019-06369-4
Kitao A, Zen Y, Matsui O et al (2010) Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR imaging–correlation with molecular transporters and histopathologic features. Radiology 256:817–826
pubmed: 20663969
doi: 10.1148/radiol.10092214
Kitao A, Matsui O, Yoneda N et al (2012) Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology 265:780–789
pubmed: 23175543
doi: 10.1148/radiol.12120226
Kambadakone AR, Fung A, Gupta RT et al (2018) LI-RADS technical requirements for CT, MRI, and contrast-enhanced ultrasound. Abdom Radiol (NY) 43:56–74
doi: 10.1007/s00261-017-1325-y
American College of Radiology. The LI-RADS v2018 Manual. https://www.acr.org/-/media/ACR/Files/Clinical-Resources/LIRADS/LI-RADS-2018-Manual-5Dec18.pdf . Accessed May 2021
Benchoufi M, Matzner-Lober E, Molinari N, Jannot AS, Soyer P (2020) Interobserver agreement issues in radiology. Diagn Interv Imaging 101:639–641
pubmed: 32958434
doi: 10.1016/j.diii.2020.09.001
Kierans AS, Makkar J, Guniganti P et al (2019) Validation of Liver Imaging Reporting and Data System 2017 (LI-RADS) criteria for imaging diagnosis of hepatocellular carcinoma. J Magn Reson Imaging 49:e205–e215
pubmed: 30257054
doi: 10.1002/jmri.26329
Shropshire E, Mamidipalli A, Wolfson T et al (2020) LI-RADS ancillary feature prediction of longitudinal category changes in LR-3 observations: an exploratory study. Abdom Radiol (NY) 45:3092–3102
doi: 10.1007/s00261-020-02429-2
Kang JH, Choi SH, Byun JH et al (2020) Ancillary features in the Liver Imaging Reporting and Data System: how to improve diagnosis of hepatocellular carcinoma ≤ 3 cm on magnetic resonance imaging. Eur Radiol 30:2881–2889
pubmed: 32020399
doi: 10.1007/s00330-019-06645-3
van der Pol CB, Dhindsa K, Shergill R et al (2021) MRI Liver Imaging Reporting and Data System (LI-RADS) version 2018: impact of and reduction in ancillary features. AJR Am J Roentgenol 216:935–942
pubmed: 33534620
doi: 10.2214/AJR.20.23031
Narita M, Hatano E, Arizono S et al (2009) Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol 44:793–798
pubmed: 19404564
doi: 10.1007/s00535-009-0056-4
Kitao A, Matsui O, Yoneda N et al (2011) The uptake transporter OATP8 expression decreases during multistep hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 21:2056–2066
pubmed: 21626360
doi: 10.1007/s00330-011-2165-8
Vernuccio F, Gagliano DS, Cannella R, Ba-Ssalamah A, Tang A, Brancatelli G (2021) Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting. Insights Imaging 12:8
pubmed: 33432491
pmcid: 7801550
doi: 10.1186/s13244-020-00928-w
Cannella R, Furlan A (2018) Mosaic architecture of hepatocellular carcinoma. Abdom Radiol (NY) 43:1847–1848
doi: 10.1007/s00261-017-1372-4
Cannella R, Vernuccio F, Sagreiya H et al (2020) Liver Imaging Reporting and Data System (LI-RADS) v2018: diagnostic value of ancillary features favoring malignancy in hypervascular observations ≥ 10 mm at intermediate (LR-3) and high probability (LR-4) for hepatocellular carcinoma. Eur Radiol 30:3770–3781
pubmed: 32107603
doi: 10.1007/s00330-020-06698-9
Song JS, Choi EJ, Hwang SB, Hwang HP, Choi H (2019) LI-RADS v2014 categorization of hepatocellular carcinoma: intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI. Eur Radiol 29:401–410
pubmed: 29922928
doi: 10.1007/s00330-018-5559-z
Ludwig DR, Fraum TJ, Cannella R et al (2019) Hepatocellular carcinoma (HCC) versus non-HCC: accuracy and reliability of Liver Imaging Reporting and Data System v2018. Abdom Radiol (NY) 44:2116–2132
doi: 10.1007/s00261-019-01948-x
Fowler KJ, Tang A, Santillan C et al (2018) Interreader reliability of LI-RADS version 2014 algorithm and imaging features for diagnosis of hepatocellular carcinoma: a large international multireader study. Radiology 286:173–185
pubmed: 29091751
doi: 10.1148/radiol.2017170376
van der Pol CB, Lim CS, Sirlin CB et al (2019) Accuracy of the Liver Imaging Reporting and Data System in computed tomography and magnetic resonance image analysis of hepatocellular carcinoma or overall malignancy-a systematic review. Gastroenterology 156:976–986
pubmed: 30445016
doi: 10.1053/j.gastro.2018.11.020
Choi SH, Byun JH, Lim YS et al (2018) Liver Imaging Reporting and Data System: patient outcomes for category 4 and 5 nodules. Radiology 287:515–524
pubmed: 29457964
doi: 10.1148/radiol.2018170748
Vernuccio F, Cannella R, Porrello G et al (2019) Uncommon imaging evolutions of focal liver lesions in cirrhosis. Abdom Radiol (NY) 44:3069–3077
doi: 10.1007/s00261-019-02101-4